PROLOR Biotech To Present At 12th Annual Oppenheimer Israeli Conference
NES-ZIONA, Israel, May 10, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the 12th Annual Oppenheimer Israeli Conference, to be held at the David Intercontinental Hotel in Tel Aviv, Israel. The presentation is scheduled for May 15, 2011 at 3:05 pm local time.
A copy of the company's updated corporate presentation, which includes an interim analysis of data from the company's Phase II trial of hGH-CTP, a long-acting version of human growth hormone, will be available starting on May 12, 2011 at the Investors section of PROLOR's website at www.prolor-biotech.com/?CategoryID=216
Shai Novik, President of PROLOR noted, "This is an exciting time for PROLOR. The recent positive results from the interim analysis of our Phase ll trial showed that one injection of hGH-CTP has the potential to replace seven daily doses of commercial human growth hormone. This sets the stage for us to complete the Phase II trial and advance preparations for our hGH-CTP Phase III registration trial planned for next year. We welcome the opportunity to discuss our pipeline and recent progress with Israeli and US investors at this important conference."
ABOUT PROLOR BIOTECHPROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and PROLOR is currently developing long-acting versions of human growth hormone, which is in Phase II clinical development, and Factor IX, Factor VII, interferon beta and erythropoietin, which are in preclinical development, as well as an anti-obesity peptide and agents for atherosclerosis and rheumatoid arthritis. For more information, visit www.prolor-biotech.com. PROLOR CONTACT: Shai Novik, PresidentPROLOR Biotech, Inc. Tel: +1 866 644-7811Email: email@example.com MEDIA CONTACT: Barbara LindheimGendeLLindheim BioCom Partners+1 212 918-4650 firstname.lastname@example.org SOURCE PROLOR Biotech, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV